Journal
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
Volume 40, Issue 7, Pages 2963-2977Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/07391102.2020.1850357
Keywords
COVID-19; SARS-CoV2; membrane glycoprotein; immunoinformatics; multi-epitope vaccine
Categories
Funding
- DSTFIST [LSI-576/2013]
Ask authors/readers for more resources
In this study, a multi-epitope vaccine targeting the membrane glycoprotein (M) on the envelopes of coronaviruses was designed using Immunoinformatics approach. The vaccine included antigenic, nonallergic, and nontoxic B-cell and T-cell epitopes. The vaccine construct consisted of multiple B-cell epitopes and was successfully cloned. Immune simulation studies showed the induction of immune responses by the vaccine.
In the present study, one of the targets present on the envelopes of coronaviruses, membrane glycoprotein (M) was chosen for the design of a multi-epitope vaccine by Immunoinformatics approach. The B-cell and T-cell epitopes used for the construction of vaccine were antigenic, nonallergic and nontoxic. An adjuvant, beta-defensin and PADRE sequence were included at the N-terminal end of the vaccine. All the epitopes were joined by linkers for decreasing the junctional immunogenicity. Various physicochemical parameters of the vaccine were evaluated. Secondary and tertiary structures were predicted for the vaccine construct. The tertiary structure was further refined, and various parameters related to the refinement of the protein structure were validated by using different tools. Humoral immunity induced by B-cells relies upon the identification of antigenic determinants on the surface of the vaccine construct. In this regard, the vaccine construct was found to consist of several B-cell epitopes in its three-dimensional conformation. Molecular docking of the vaccine was carried out with TLR-3 receptor to study their binding and its strength. Further, protein-protein interactions in the docked complex were visualized using LigPlot+. Population coverage analysis had shown that the multi-epitope vaccine covers 94.06% of the global population. The vaccine construct was successfully cloned in silico into pET-28a (+). Immune simulation studies showed the induction of primary, secondary and tertiary immune responses marked by the increased levels of antibodies, INF-gamma, IL-2, TGF-beta, B- cells, CD4+ and CD8+ cells. Finally, the vaccine construct was able to elicit immune response as desired. Communicated by Ramaswamy H. Sarma
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available